Clinical Trials
US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India
US pharmaceutical giant Gilead Sciences is likely to apply to India's Central Drugs Standard Control Organisation (CDSCO) soon seeking marketing authorisation for its anti-viral drug remdesivir, which is being considered by many as a potential medication for COVID-19.
Officials of...
Clinical Trials
Pfizer reports gene therapy data from Phase Ib DMD trial
Pfizer has reported new data from the Phase Ib clinical trial of PF-06939926 for the treatment of patients with Duchenne muscular dystrophy (DMD).
PF-06939926 is an experimental, recombinant adeno-associated virus serotype 9 (AAV9) capsid with a shortened variant of the...
News
Clinigen Signs Exclusive Agreement with Xeris to Supply, Distribute Gvoke Outside US
Clinigen Group has signed an exclusive agreement with Xeris Pharmaceuticals to manage the supply and distribution of Gvoke injection, a treatment for diabetes, outside the US.
Under the terms of the supply and distribution agreement with Xeris, Clinigen will provide...
News
Parexel, ACRO Joins to Help Administer and Oversee COVID-19 Testing in UK
Parexel announced the deployment of nearly 30 employee volunteers to help administer and oversee COVID-19 testing across the UK in partnership with the Association of Clinical Research Organizations (ACRO).
The Parexel volunteers are among a team of 150 individuals with...
News
DefiniGEN Launches Tool for Coronavirus-Specific Intestinal Cell Research
DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients.
While SARS-CoV-2 primarily targets the respiratory system, studies have shown it also infects...
News
Cellect Biotechnologys ApoGraft to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases
Cellect Biotechnology Ltd., a developer of innovative technology which enables the functional selection of stem cells, announced that it has signed a development agreement with an international consortium to examine the therapeutic effects of ApoGraft treated stem cells on...
News
DTx Pharma Expands Footprint in San Diego with New Office and Lab Space
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced the expansion of its footprint into a new 14,000 square foot lab and office space, located at 10655 Sorrento...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read